The Impact Of Landmark Response On Overall Survival: Implications For The Economic Evaluation Of Immune-Therapy (I-O) Treatment

October 18, 2018 Danielle Twigg

Initial results from CheckMate 032, a Phase 1/2 clinical trial, showed durable responses and encouraging survival with nivolumab-based regimens in SCLC patients after previous platinum-containing regimens. Response-based modeling has been proposed to capture extended OS associated with I-O treatment. We examine the relationship between patients’ response status at a landmark and OS by treatment arm.

Authors: Irene Santi, Caitlin Smare, Ariadna Juarez-Garcia, D. Ross Camidge, Nancy Schoenherr, John R. Penrod, Pranav Abraham, Beata Korytowsky, Yong Yuan

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
The Rise Of The Non-Submission – A Worrying Trend For UK Patient Access With ‘Brexit’ Approaching
The Rise Of The Non-Submission – A Worrying Trend For UK Patient Access With ‘Brexit’ Approaching

Next Article
Spanish Therapeutic Positioning Reports: 6-Year Update – Increasing In Frequency But Not Relevance?
Spanish Therapeutic Positioning Reports: 6-Year Update – Increasing In Frequency But Not Relevance?